The Cooper Companies, Inc. (COO) slumps 17.5% after earnings
The Cooper Companies, Inc. (COO) slumps after fiscal Q3 earnings, updated guidance, and a completed strategic review disappointed investors. A small EPS miss, weaker CooperVision revenue, and reduced takeover hopes sparked the sharp extended-hours drop.
The Cooper Companies, Inc. (COO) slumps 17.5% in extended-hours trading after fiscal Q3 earnings missed estimates, guidance was cut, and the company ended its strategic review without a transformative transaction. The selloff reflects weaker CooperVision demand, inventory reduction headwinds, and fading takeover speculation, all of which pressure near-term sentiment for investors.
The Cooper Companies, Inc. (COO) Slumps After Earnings
The Cooper Companies, Inc. (COO) slumps in extended-hours trading, printing $52.40 versus the prior regular-session close of $63.48, a 17.45% drop. The move follows fiscal Q3 2026 earnings, updated full-year guidance, and a completed strategic review; regular-session trading will confirm whether the break holds.
Key Takeaways
COO printed $52.40 in extended-hours trading, down 17.45% from the prior close of $63.48.
Fiscal Q3 EPS came in at $1.10 versus a $1.11 estimate, a 0.9% miss.
CooperVision revenue fell to $717M from $723.5M in the prior quarter, while channel inventory reductions will affect Q4.
The strategic review ended without a transformative transaction, removing sale speculation around CooperSurgical.
Fresh analyst downgrades and price-target cuts reinforce a more cautious view, despite a consensus rating that still lists 16 buys.
Why The Cooper Companies (COO) Is Slumping After Q3 Earnings
The most likely catalyst is the September 9 fiscal Q3 2026 earnings update. COO posted EPS of $1.10, below the $1.11 estimate, producing a 0.9% miss. The number was small, but the message around future earnings was larger. The company also updated full-year fiscal 2026 guidance after weak contact lens demand.
CooperVision supplied the clearest operating pressure. Revenue reached $717M for the quarter ended July 31, down from $723.5M in the prior quarter. CEO Albert White said COO reduced US channel inventory, and that action will continue to weigh on Q4. That gives the selloff a concrete business link, not just a chart-based explanation.
Q4 EPS guidance of $1.05-$1.09 adds a defined near-term constraint. The range gives investors a lower earnings frame than the $1.10 Q3 actual, while the inventory comment explains why the next quarter faces pressure. COO also cut its annual profit forecast after the contact lens weakness.
The strategic review adds a second catalyst. COO completed a review announced in December 2025 after speculation about a sale of CooperSurgical. The process did not produce a disclosed sale or breakup. The board cited a competitive entrant in the non-hormonal IUD market and a fertility litigation settlement among factors affecting perceived valuation. That likely disappointed investors who had priced in strategic optionality.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
COO's Guidance and CooperVision Weakness Set the Tone
Fundamentally, COO remains a focused medical device company with two operating businesses. CooperVision sells spherical, toric, and multifocal lenses for astigmatism, presbyopia, and myopia. CooperSurgical serves fertility, women's health, medical devices, and contraception. This mix provides recurring lens demand alongside a broader health-care portfolio, but it also exposes earnings to different risks.
CooperVision is the larger and more visible franchise, so the decline from $723.5M to $717M matters disproportionately. The business also holds positions in premium lenses and myopia-control products, which support its competitive standing. However, product strength does not shield results from channel inventory corrections.
CooperSurgical delivered solid fertility growth in Q3, according to White. Still, that segment carries litigation, regulatory, and product-cycle risk. The fertility settlement and IUD competition put those risks into the current valuation debate. The result is a company with useful diversification, but no clean escape from near-term execution concerns.
Prior earnings history makes Q3 stand out. COO beat EPS estimates in 7 of the previous 8 quarters, but Q3 actual EPS missed by 0.9%. A single miss does not erase that record. However, it carries more weight when paired with an annual profit forecast cut and softness in the core contact lens segment.
COO Valuation Faces a Sharper Test After the Selloff
Valuation is not a footnote. The listed P/E is 57.19, while market cap is $12.38B. That multiple left little room for an earnings miss or a strategic-review result that removed takeover speculation. A sharp price drop can improve valuation, but it does not automatically make the stock cheap. Earnings power must catch up with the valuation reset.
The technical reset is severe. The $52.40 extended-hours print sits below the listed 52-week low of $58.89 and far below the $89.83 high. The regular session matters because it will show whether buyers absorb supply at the new price. A sustained recovery would require more than a rebound from an oversold level.
Analyst actions reinforce the reset. Piper Sandler downgraded COO from Overweight to Neutral, while Baird also moved to Neutral. Wells Fargo lowered its target from $66 to $61. Stifel and Needham posted targets of $70 and $73. Consensus still lists 16 buys, 8 holds, and 1 sell, but the latest actions are more cautious.
Quantified news sentiment remained strongly positive, with a 7-day score of 0.9833 and a stable trend. That contrast matters. Older headlines had not turned broadly negative, but the hard earnings and guidance facts changed the price narrative quickly.
The forward picture has both repair levers and risks. Management cited record free cash flow, solid fertility growth, and favorable completion of a tax matter. COO also added $1B to its buyback authorization. Those facts support capital flexibility, but buybacks cannot fix weak demand by themselves.
Near-term evidence is less flattering. Q4 EPS guidance is $1.05-$1.09, and the CEO said channel inventory reduction will continue to affect Q4. That puts CooperVision execution at the center of the investment thesis. A durable recovery needs demand and inventory conditions to improve, not merely a lower share price.
A disciplined approach is to judge the thesis against hard operating markers. Those include the Q4 guidance range, CooperVision revenue after the $717M Q3 result, and the effect of strategic-review concerns on CooperSurgical. New buyers face a higher bar because the stock trades below its listed 52-week low, yet the listed P/E remains 57.19.
The best case rests on CooperVision recovering from the inventory correction while CooperSurgical sustains fertility growth. The risk case involves continued contact lens weakness, fresh competitive pressure, or additional litigation costs. Those opposing forces make COO a recovery situation rather than a simple bargain trade.
COO's after-hours slump is best explained by a 0.9% EPS miss, annual outlook pressure from weak contact lens demand, and strategic-review disappointment, then amplified by downgrades and target cuts. The business still has product depth, fertility growth, record free cash flow, and a $1B buyback authorization, but investors now need operational recovery to justify paying for that potential.
COO is down after fiscal Q3 EPS missed estimates, full-year guidance was lowered, and CooperVision revenue weakened. Investors also reacted to the completed strategic review, which did not result in a major sale or breakup.
+Should I buy COO stock now?
Not aggressively based on this report. The stock’s valuation has reset lower, but near-term earnings pressure, weaker contact lens demand, and inventory reduction risks still argue for caution.
+Did The Cooper Companies miss earnings?
Yes. Fiscal Q3 EPS came in at $1.10 versus a $1.11 estimate, a small miss. The bigger issue was the weaker outlook and reduced guidance for the rest of the year.
+What does the strategic review mean for COO investors?
It means the company did not announce a transformative transaction, so takeover speculation has faded. That removes a potential valuation catalyst and leaves investors focused on operating performance instead.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on COO?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
